Randomized Cross‐Over Study to Examine Associations Between Dialyzer Clotting, Uremic Toxin Removal, and Hemocompatibility During Post‐Dilution Hemodiafiltration With Reduced Anticoagulation

To date, it remains unclear to what extent dialyzer performance is affected by clotting, and which hemocompatibility parameters can reliably predict this phenomenon. This study investigated the relationship between dialyzer clotting, performance, and hemocompatibility in four commercially available dialyzers under conditions of intentionally reduced anticoagulation. This crossover study included 10 chronic hemodialysis patients, who were randomized over four dialyzers: FX CorAL800, FX CorDiax800, xevonta Hi20 (all polysulfone-based), and Solacea-19H (cellulose-based). Patients received a single bolus of one-quarter of their standard Low-Molecular-Weight Heparin (LMWH) dose. Dialysis efficiency was assessed from toxin clearance of urea, β2-microglobulin, and myoglobin. Fiber patency was evaluated through visual scoring and μCT imaging. Hemocompatibility markers, including platelet counts, leukocyte counts, anti-Xa activity, thrombin-antithrombin complex (TAT), beta-thromboglobulin (β-TG), and neutrophil-activating peptide (NAP-2), were also analyzed. μCT analysis showed that Solacea dialyzer demonstrated superior fiber patency compared to the other dialyzers. However, fiber blockage did not compromise dialysis performance, as all dialyzers maintained effective toxin removal. Platelet and leukocyte counts remained stable with FX CorAL and Solacea, while declines were found in FX CorDiax and xevonta. No significant correlations were found between clotting parameters and fiber blockage. Hence, under reduced anticoagulation, the cellulose-based Solacea dialyzer exhibited superior fiber patency, but this did not result in higher middle molecule clearance. Since no correlation was found between fiber patency, dialysis performance, or clotting parameters, the underlying cause of the observed differences in dialyzer blockage remains unclear.

Authors

Institutions

Publication Details

Journal
Artificial Organs
Published
2025-11-23
DOI
https://doi.org/10.1111/aor.70039
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomized Cross‐Over Study to Examine Associations Between Dialyzer Clotting, Uremic Toxin Removal, and Hemocompatibility During Post‐Dilution Hemodiafiltration With Reduced Anticoagulation

Filip De Somer, Iván Josipovic, Sunny Eloot, Adam M. Zawada et al.
Artificial Organs
Dialysis and Renal Disease Management
article

Randomized Cross‐Over Study to Examine Associations Between Dialyzer Clotting, Uremic Toxin Removal, and Hemocompatibility During Post‐Dilution Hemodiafiltration With Reduced Anticoagulation

Filip De Somer, Iván Josipovic, Sunny Eloot, Adam M. Zawada, Floris Vanommeslaeghe, Wim Van Biesen, Bettina Griesshaber, Alfred Gagel, Ansgar Erlenkötter, Katrien Devreese, Griet Glorieux, Matthieu Boone
article en

Abstract

To date, it remains unclear to what extent dialyzer performance is affected by clotting, and which hemocompatibility parameters can reliably predict this phenomenon. This study investigated the relationship between dialyzer clotting, performance, and hemocompatibility in four commercially available dialyzers under conditions of intentionally reduced anticoagulation. This crossover study included 10 chronic hemodialysis patients, who were randomized over four dialyzers: FX CorAL800, FX CorDiax800, xevonta Hi20 (all polysulfone-based), and Solacea-19H (cellulose-based). Patients received a single bolus of one-quarter of their standard Low-Molecular-Weight Heparin (LMWH) dose. Dialysis efficiency was assessed from toxin clearance of urea, β2-microglobulin, and myoglobin. Fiber patency was evaluated through visual scoring and μCT imaging. Hemocompatibility markers, including platelet counts, leukocyte counts, anti-Xa activity, thrombin-antithrombin complex (TAT), beta-thromboglobulin (β-TG), and neutrophil-activating peptide (NAP-2), were also analyzed. μCT analysis showed that Solacea dialyzer demonstrated superior fiber patency compared to the other dialyzers. However, fiber blockage did not compromise dialysis performance, as all dialyzers maintained effective toxin removal. Platelet and leukocyte counts remained stable with FX CorAL and Solacea, while declines were found in FX CorDiax and xevonta. No significant correlations were found between clotting parameters and fiber blockage. Hence, under reduced anticoagulation, the cellulose-based Solacea dialyzer exhibited superior fiber patency, but this did not result in higher middle molecule clearance. Since no correlation was found between fiber patency, dialysis performance, or clotting parameters, the underlying cause of the observed differences in dialyzer blockage remains unclear.

Artificial OrgansVol. 50(1)
Ghent University Hospital (BE), Ghent University (BE), Fresenius Medical Care (Germany) (DE)
Openalex Percentile: Top 57%
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.